Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A

Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A

SSSE:603456
16.02
CNY
-0.18
(-1.11%)
0.66EPS
24.69P/E
14.67BMarket Cap
Apr 23Next Earn

Total Valuation

CNY

As of September 30, 2026, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A carries a market capitalization of 14.67B, placing it among publicly traded companies globally. Its enterprise value stands at 13.40B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap14.67B
Enterprise Value13.40B

Important Dates

Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for April 23, 2027.

Earnings Date4/23/2027

Share Statistics

As of September 30, 2026, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A has 875.54M shares outstanding.

Shares Outstanding875.54M

Valuation Ratios

As of September 30, 2026, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 24.69. The price-to-sales ratio is 2.80, and the price-to-book ratio stands at 1.64.

PE Ratio24.69
PS Ratio2.80
PB Ratio1.64
P/TBV Ratio1.74

Enterprise Valuation

As of September 30, 2026, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 17.35 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.54 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 17.35 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 13.40B versus a market cap of 14.67B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.54
EV / EBITDA17.35
EV / EBIT17.35

Financial Position

As of September 30, 2026, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A maintains a current ratio of 3.56, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.14, indicating conservative leverage, while an interest coverage ratio of 99.64 demonstrates strong ability to service its debt obligations.

Current Ratio3.56
Quick Ratio0.81
Debt / Equity0.14
Debt / EBITDA0.02
Interest Coverage99.64

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 6.79, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.43 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.49, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.79, useful for judging operating efficiency across full business cycles. The company generates approximately 1.10M in revenue per employee across its workforce of 4,791.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.12 indicates how many times Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)6.79
Return on Assets (ROA)5.49
Return on Invested Capital (ROIC)6.43
Return on Capital Employed (ROCE)6.79
Revenue Per Employee1.10M
Employee Count4,791.00
Inventory Turnover2.12

Taxes

CNY

Over the twelve months ended September 30, 2026, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A recorded 180.70M in income tax expense. That works out to an effective tax rate of 23.54, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 767.53M, leaving 599.20M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax180.70M
Effective Tax Rate23.54

Stock Price Statistics

CNY

As of the close on November 17, 2026, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A's stock has declined approximately 26.75% over the past 52 weeks. The 50-day moving average sits at 15.90, while the 200-day moving average is 15.64.

52-Week Price Change-26.75%
50-Day Moving Average15.90
200-Day Moving Average15.64

Income Statement

CNY

Over the twelve months ended September 30, 2026, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A generated 5.28B in revenue and converted that into 599.20M in net income, yielding earnings per share of 0.66. EBITDA reached 772.42M, while operating income came in at 1.09B.

Revenue5.28B
Gross Profit1.89B
Operating Income1.09B
Pretax Income767.53M
Net Income599.20M
EBITDA772.42M
EBIT772.42M
Earnings Per Share (EPS)0.66

Balance Sheet

CNY

As of September 30, 2026, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A holds 1.34B in cash and equivalents against 12.71M in total debt, resulting in a net debt position of -1.34B. Total book value stands at 8.93B, with working capital of 4.20B providing operational flexibility.

Cash & Cash Equivalents1.34B
Total Debt12.71M
Net Debt-1.34B
Equity (Book Value)8.93B
Book Value Per Share10.20
Working Capital4.20B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-562.69M

Margins

Over the twelve months ended September 30, 2026, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A posted a gross margin of 35.80, reflecting its pricing power and cost economics. The operating margin of 20.54 and net profit margin of 11.34 provide insight into operational efficiency.

Gross Margin35.80
Operating Margin20.54
Pretax Margin14.52
Profit Margin11.34
EBITDA Margin14.62

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A paid dividends of 0.20 per share. The dividend payout ratio of 30.72 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 3.66, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.20
Payout Ratio30.72
Shareholder Yield3.66

Stock Splits

Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A's most recent stock split took place on April 12, 2018 with a 5:9 split ratio.

Last Split Date4/12/2018
Split Ratio5:9

Scores

As of September 30, 2026, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 6.55, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.55